fda approves first oral glp-1 obesity drug august 1 2025 for Weight Loss FDA Approves First ORAL GLP-1

How long will I need to take the medication

Glucagon-like peptide-1 receptor (GLP-1R) agonists are effective anti-obesity drugs but their use is limited by side effects

In STEP 1, patients with obesity (without diabetes) lost nearly 15% of body weight on weekly semaglutide

Somatostatin, secreted from pancreatic -cells, acts as an inhibitory paracrine to suppress glucagon release from pancreatic -cells, and specific blockade of SSRT2 eliminates the inhibitory effect of GLP-1 on glucagon secretion

With the right strategies and support from the Hopkins MD team, you can minimize discomfort and focus on the benefits these medications offer